These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32447126)

  • 1. The CITIMEM study: A pilot study. Optimizing pharmacological treatment in dementia.
    Gareri P; Cotroneo AM; Orsitto G; Putignano S
    Arch Gerontol Geriatr; 2020; 89():104073. PubMed ID: 32447126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study.
    Gareri P; Castagna A; Cotroneo AM; Putignano D; Conforti R; Santamaria F; Marino S; Putignano S
    J Alzheimers Dis; 2017; 56(2):557-565. PubMed ID: 28035929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Importance of Citicoline in Combined Treatment in Dementia: What did the Citimem Study Teach us?
    Gareri P; Cotroneo AM; Orsitto G; Putignano S
    Rev Recent Clin Trials; 2021; 16(2):126-130. PubMed ID: 33243132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in Older Patients Affected with Alzheimer's Disease.
    Castagna A; Manzo C; Fabbo A; Lacava R; Ruberto C; Ruotolo G
    Clin Drug Investig; 2021 Feb; 41(2):177-182. PubMed ID: 33484469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study.
    Castagna A; Cotroneo AM; Ruotolo G; Gareri P
    Clin Drug Investig; 2016 Dec; 36(12):1059-1065. PubMed ID: 27587069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Citicoline: A Cholinergic Precursor with a Pivotal Role in Dementia and Alzheimer's Disease.
    Gareri P; Cotroneo AM; Montella R; Gaglianone M; Putignano S
    J Alzheimers Dis; 2024; 100(2):725-733. PubMed ID: 38905051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Study on the Benefits of Combined Citicoline, Memantine, and Acetylcholinesterase Inhibitor Treatments in Older Patients Affected with Alzheimer's Disease.
    Castagna A; Fabbo A; Manzo C; Lacava R; Ruberto C; Ruotolo G
    J Alzheimers Dis; 2021; 79(4):1509-1515. PubMed ID: 33459645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study.
    Cotroneo AM; Castagna A; Putignano S; Lacava R; Fantò F; Monteleone F; Rocca F; Malara A; Gareri P
    Clin Interv Aging; 2013; 8():131-7. PubMed ID: 23403474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive changes under memantine according to vitamin D status in Alzheimer patients: An exposed/unexposed cohort pilot study.
    Lemire P; Brangier A; Beaudenon M; Duval GT; Annweiler C
    J Steroid Biochem Mol Biol; 2018 Jan; 175():151-156. PubMed ID: 28042052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Overview of Combination Treatment with Citicoline in Dementia.
    Gareri P; Veronese N; Cotroneo AM
    Rev Recent Clin Trials; 2022; 17(1):4-8. PubMed ID: 34939548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.
    Ott BR; Blake LM; Kagan E; Resnick M;
    J Neurol; 2007 Mar; 254(3):351-8. PubMed ID: 17345042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Memantine: from the original brand to generics].
    Titova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):136-143. PubMed ID: 29171502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study.
    Annweiler C; Herrmann FR; Fantino B; Brugg B; Beauchet O
    Cogn Behav Neurol; 2012 Sep; 25(3):121-7. PubMed ID: 22960436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
    Olin JT; Bhatnagar V; Reyes P; Koumaras B; Meng X; Brannan S
    Int J Geriatr Psychiatry; 2010 Apr; 25(4):419-26. PubMed ID: 19670390
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.